Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month Low – Here’s What Happened

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s stock price hit a new 52-week low on Monday . The company traded as low as $15.63 and last traded at $15.71, with a volume of 168337 shares trading hands. The stock had previously closed at $16.21.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on KLRA shares. TD Cowen began coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $57.00 price objective for the company. Leerink Partners started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 target price on the stock. Jefferies Financial Group started coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $48.00 price target on the stock. Weiss Ratings started coverage on shares of Kailera Therapeutics in a report on Friday, August 14th. They issued a “sell (d)” rating for the company. Finally, Evercore started coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Kailera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $42.75.

Kailera Therapeutics Stock Performance

The firm has a market cap of $2.02 billion and a price-to-earnings ratio of -0.00. The firm’s fifty day moving average price is $19.09.

Kailera Therapeutics (NASDAQ:KLRA) last posted its earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). Research analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kailera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System bought a new stake in Kailera Therapeutics in the 2nd quarter valued at $309,000. Frazier Life Sciences Management L.P. bought a new position in Kailera Therapeutics during the 2nd quarter worth about $24,233,000. Wellington Management Group LLP bought a new position in Kailera Therapeutics during the 2nd quarter worth about $64,308,000. Finally, Atlas Venture Life Science Advisors LLC acquired a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at about $113,923,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.